Sanofi (NYSE:SNY) was upgraded by equities research analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research report issued on Tuesday.

SNY has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, October 27th. Leerink Swann restated a “buy” rating on shares of Sanofi in a research report on Monday, September 26th. Goldman Sachs Group Inc. began coverage on shares of Sanofi in a research report on Monday, November 7th. They set a “neutral” rating on the stock. Jefferies Group restated a “hold” rating on shares of Sanofi in a research report on Wednesday, September 14th. Finally, JPMorgan Chase & Co. restated an “underweight” rating on shares of Sanofi in a research report on Thursday, September 15th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $60.50.

Analyst Recommendations for Sanofi (NYSE:SNY)

Shares of Sanofi (NYSE:SNY) opened at 40.20 on Tuesday. Sanofi has a 52-week low of $36.81 and a 52-week high of $44.50. The stock’s 50 day moving average price is $39.28 and its 200-day moving average price is $39.83. The stock has a market cap of $103.48 billion, a price-to-earnings ratio of 23.31 and a beta of 0.97.

ILLEGAL ACTIVITY NOTICE: “Morgan Stanley Upgrades Sanofi (SNY) to “Overweight”” was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2016/12/01/morgan-stanley-upgrades-sanofi-sny-to-overweight.html.

Institutional investors have recently modified their holdings of the stock. CKW Financial Group increased its position in shares of Sanofi by 21.6% in the third quarter. CKW Financial Group now owns 2,816 shares of the company’s stock worth $108,000 after buying an additional 500 shares in the last quarter. Bessemer Group Inc. increased its position in shares of Sanofi by 77.1% in the second quarter. Bessemer Group Inc. now owns 3,445 shares of the company’s stock worth $144,000 after buying an additional 1,500 shares in the last quarter. Signaturefd LLC increased its position in shares of Sanofi by 16.4% in the second quarter. Signaturefd LLC now owns 3,480 shares of the company’s stock worth $146,000 after buying an additional 490 shares in the last quarter. JFS Wealth Advisors LLC increased its position in shares of Sanofi by 3.5% in the second quarter. JFS Wealth Advisors LLC now owns 3,961 shares of the company’s stock worth $166,000 after buying an additional 134 shares in the last quarter. Finally, Jacobi Capital Management LLC increased its position in shares of Sanofi by 31.9% in the third quarter. Jacobi Capital Management LLC now owns 4,271 shares of the company’s stock worth $164,000 after buying an additional 1,034 shares in the last quarter. 9.80% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

5 Day Chart for NYSE:SNY

Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.